Today: 27 June 2026
Browse Category

Stock Market 25 January 2026

Northern Star share price: NST jumps 5% as gold hits records, but costs and broker nerves linger

Northern Star share price: NST jumps 5% as gold hits records, but costs and broker nerves linger

Northern Star Resources rose 5.4% to A$27.60 Friday as gold prices neared record highs, despite the company raising its FY26 cost forecast to A$2,600–A$2,800 per ounce. UBS downgraded the stock to Neutral on Jan. 22. The miner reported December quarter gold sales of 348,061 ounces at an AISC of A$2,937. Half-year results are due Feb. 12.
25 January 2026
····
PLS Group share price sits near a peak as traders brace for a holiday-shortened week and Jan 30 update

PLS Group share price sits near a peak as traders brace for a holiday-shortened week and Jan 30 update

PLS Group Limited shares closed Friday at A$5.08, up 0.8%, near a 52-week high after a strong January rally. The company will release its December quarterly activities report on Jan. 30, with traders watching for updates on production, prices, and costs. Nearly 39 million shares traded Friday. The ASX will be closed Monday for the Australia Day holiday, delaying the market’s response to new information until Tuesday.
25 January 2026
·
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 25.01.2026

USA Rare Earth shares jumped 40% after the company announced progress at its Texas project and the U.S. government disclosed plans for a $1.6 billion stake. UFP Technologies closed at $258.68, up 9% in 30 days, as valuation debates continue. Analysts urge caution with high-yield stocks, highlighting stable cash flow and strong balance sheets as key for safe income investments in 2026.
25 January 2026
Xi’an ESWIN stock price: Friday lift for 688783, but a loss forecast still sets the tone

Xi’an ESWIN stock price: Friday lift for 688783, but a loss forecast still sets the tone

Xi'an ESWIN Material Technology closed up 1.18% at 26.66 yuan Friday in Shanghai, with turnover near 374 million yuan. The company projects 2025 revenue of 2.65 billion yuan but expects a net loss of 738 million yuan, citing weak wafer demand and higher R&D costs. Shareholder count dropped 10% in January. The audited annual report is due April 21.
25 January 2026
··
MACOM (MTSI) stock slips into next week as chip jitters return and Feb. 5 earnings loom

MACOM (MTSI) stock slips into next week as chip jitters return and Feb. 5 earnings loom

MACOM Technology Solutions shares fell 2.3% to $219.26 at Friday’s close. The company will report first-quarter results before the market opens on Feb. 5, with a conference call at 8:30 a.m. ET. Chip stocks broadly declined, including Broadcom, Marvell, Lumentum, and Coherent. Investors are watching for signals on demand in data center and telecom sectors amid sector volatility.
25 January 2026
····
Suzhou TFC Optical (300394.SZ) stock slides 5% into weekend as traders eye leverage, AI optics demand

Suzhou TFC Optical (300394.SZ) stock slides 5% into weekend as traders eye leverage, AI optics demand

Suzhou TFC Optical Communication Class A shares fell 5.4% to 189.16 yuan in Shanghai on Friday, bucking gains in the ChiNext Index. Margin financing in the stock remained elevated after a surge earlier in the week. Analysts cited tight supply of upstream optical chips and currency swings as immediate risks. The company recently forecast 2025 net profit up 40–60% year-on-year, but flagged foreign-exchange losses.
25 January 2026
·
STMicroelectronics stock price: analyst targets rise into earnings week as shares hold steady

STMicroelectronics stock price: analyst targets rise into earnings week as shares hold steady

STMicroelectronics shares closed Friday at 24.65 euros, up 0.02%, after two broker notes ahead of next week’s earnings. Berenberg raised its price target to 29 euros, while Intesa Sanpaolo started coverage at neutral. Investors are watching for signs of demand trends in autos and industry when results are released Jan. 29.
25 January 2026
····
GlobalFoundries (GFS) stock slides nearly 5%: what investors watch before Monday’s open

GlobalFoundries (GFS) stock slides nearly 5%: what investors watch before Monday’s open

GlobalFoundries shares fell 4.8% Friday to $42.85, with 4.3 million shares traded. The drop follows Intel’s weak outlook and comes ahead of the Federal Reserve’s Jan. 27–28 meeting. GlobalFoundries will report earnings Feb. 11. The company recently agreed to acquire Synopsys’ ARC Processor IP business and added Ganesh Moorthy to its board.
25 January 2026
···
ON Semiconductor stock heads into week ahead with Feb. 9 earnings date now the next big test

ON Semiconductor stock heads into week ahead with Feb. 9 earnings date now the next big test

ON Semiconductor shares fell 1.7% to $61.98 Friday, closing about 6% below their 52-week high. The company will report fourth-quarter and full-year results after markets close Feb. 9, with a call at 5 p.m. ET. The PHLX Semiconductor Index dropped 1.21% to 7,957.93. The Federal Reserve’s rate decision on Jan. 28 is seen as a near-term risk for chip stocks.
25 January 2026
··
Hua Hong Semiconductor Class A stock: Feb 10 deal vote is the next test for 688347

Hua Hong Semiconductor Class A stock: Feb 10 deal vote is the next test for 688347

Hua Hong Semiconductor’s Class A shares closed down 0.6% at 139.76 yuan in Shanghai on Friday. Shareholders are set to vote February 10 on issuing new shares to acquire nearly all of Shanghai Huali Microelectronics for about 8.27 billion yuan and on a private placement to raise up to 7.56 billion yuan. The deals face scrutiny over pricing, dilution, and regulatory progress.
25 January 2026
·
1 … 595 596 597 598 599 … 1,596

Stock Market Today

  • Telix Pharmaceuticals and Two Australian Insider-Led Growth Stocks Highlighted
    June 27, 2026, 11:07 AM EDT. Telix Pharmaceuticals (ASX:TLX), a A$5.2 billion biopharmaceutical firm specializing in radiopharmaceuticals for cancer imaging and treatment, draws growth-focused investors despite ongoing losses. The company reported US$621.9 million revenue from Precision Medicine and relies heavily on its oncology pipeline with products like Illuccix and late-stage candidates TLX591 and TLX101. Key risks include high R&D costs, regulatory scrutiny, pricing pressures, and trial dependencies. Also featured are two Australian insider-led growth stocks identified by the Fast Growing Stocks With High Insider Ownership screener, highlighting firms with aligned management-shareholder interests amid mixed inflation and cautious central bank policies.

Latest articles

Generate Biomedicines stock ends week back above IPO price as volume jumps

Generate Biomedicines stock ends week back above IPO price as volume jumps

27 June 2026
Generate Biomedicines (NASDAQ:GENB) surged 13.7% since June 18 to close Friday at $16.47—above its $16 IPO price—with heavy volume and a $2.11B market cap, as investors weigh its $516.6M cash pile, ongoing clinical trial risks, and lack of product revenue, while sector momentum lifts biotech stocks.
Snowflake (NYSE:SNOW) finishes up for the week after Russell rebalance trading

Snowflake (NYSE:SNOW) finishes up for the week after Russell rebalance trading

27 June 2026
Snowflake Inc (NYSE:SNOW) surged 9.65% to $248.96 on Friday with trading volume five times the weekly average, driven by FTSE Russell’s U.S. index reconstitution, turning a negative week into a 7.2% gain since June 18, as investors await whether the stock can hold above its previous $225.95–$230.41 range when index-driven liquidity fades next week.
GameStop (NYSE:GME) holds close to cash levels after company guides for $600 million in EBITDA

GameStop (NYSE:GME) holds close to cash levels after company guides for $600 million in EBITDA

27 June 2026
GameStop surged 3.57% to $21.76 and jumped after hours as it forecast FY2026 adjusted EBITDA above $600 million, nearly doubling from 2025; with a $9.76 billion market cap now close to its $9.7 billion in cash, securities, digital assets, and collateral, investors are weighing whether GameStop’s cash-rich balance sheet can support equity while Ryan Cohen pursues an eBay bid.
ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume

ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume

27 June 2026
ImmunityBio surged 11.8% to $8.71 on Friday with volume tripling its average, as Russell index reconstitution took effect; Monday’s trading will reveal if demand persists or if the spike was driven by index flows, with no imminent company events and recent insider selling accounting for just 0.06% of Friday’s volume.
Go toTop